BALAXI PHARMACEUTICALS LIMITED

400 billion

rcing Regions , Ne full Pine “We. . yo Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion Key Milestones Started business

6 billion

e. . yo Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion Key Milestones Started business supplying white labelled product

INR 49.36 crore

ntral African Republic Successfully completed fund raising exercise through Preferential issue — INR 49.36 crore Capex plans — Project initiated for our first Pharma, Formulation manufacturing facility in Hyde

37%

s in the Latin American markets — Guatemala, Honduras and El Salvador. These LATAM markets grew by 37% and have contributed 40% of our pharmaceuticals revenues and we are confident of increasing this f

40%

arkets — Guatemala, Honduras and El Salvador. These LATAM markets grew by 37% and have contributed 40% of our pharmaceuticals revenues and we are confident of increasing this further as we penetrate th

60%

s. Our mature presence in Angola has also contributed with another steady performance contributing 60% of the pharmaceuticals business. and currency depreciation, issues, As on 31 March, the numbe

30.0%

rgin % EBITDA EBITDA Margin % Profit After Tax PAT Margin % Tea eee hay) ae ve cE WL 30.0% 55.18 Ley rW As: rea 47.66 NOTE: Financial Results for FY23 are not strictly comparable with

20%

ry Revenue =" \ Higher contribution from the pharmaceuticals business led to y-o-y growth of 20% in revenues for FY23 compared to FY22. The share of LATAM markets increased to 40% of pharmaceutic

Rs. 59.17 crore

e-invested for expanding into new markets. EBITDA = During the year, operating EBITDA stood at Rs. 59.17 crore, a growth of 7.2% y-o-y. This was on account of increasing contribution from LATAM markets and exp

7.2%

new markets. EBITDA = During the year, operating EBITDA stood at Rs. 59.17 crore, a growth of 7.2% y-o-y. This was on account of increasing contribution from LATAM markets and expansion into newer

200 bps

bution from LATAM markets and expansion into newer geographies. EBITDA margin has declined by over 200 bps to 17.6% in FY23 — however, going forward with contribution from the newly entered market rising,

17.6%

LATAM markets and expansion into newer geographies. EBITDA margin has declined by over 200 bps to 17.6% in FY23 — however, going forward with contribution from the newly entered market rising, there sho

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“With the increase in the number of product offerings, we expect to further increase our market share in the countries of our focus.”

“We also plan to launch our operations in new countries in these regions.”

“EBITDA margin has declined by over 200 bps to 17.6% in FY23 — however, going forward with contribution from the newly entered market rising, there should be a steady rise in our margins.”

Expansion initiated

1

Expansion initiated

Nicaragua, Ecuador, Chile (Latin America) 808 product registrations in six countries 700 registrations submitted or in the pipeline Establishing the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other plobal markets over near to medium term management and customized CRM tools Centralized digital procurement, regulatory Key Success Factors Market Selection Methodology =" Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep understanding of demand dynamics As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management Established unique ecosystem of 100+ Indian expatriates in operating geographies Financial security ecosystem for key personnel, creating a h